{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:40:56Z","timestamp":1791333656368,"version":"4.3.1"},"reference-count":192,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":844,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001655","name":"Deutscher Akademischer Austauschdienst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Biomembranes"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.bbamem.2010.12.017","type":"journal-article","created":{"date-parts":[[2010,12,24]],"date-time":"2010-12-24T04:19:35Z","timestamp":1293164375000},"page":"1290-1308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":396,"title":["Recent developments in adenosine receptor ligands and their potential as novel drugs"],"prefix":"10.1016","volume":"1808","author":[{"given":"Christa E.","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbamem.2010.12.017_bb0005","unstructured":"B.B. Fredholm, A.P. IJzerman, K.A. Jacobson, J. Linden, C.E. M\u00fcller, Nomenclature and classification of adenosine receptors \u2014 an update. Pharmacol. Rev., (in press)."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0010","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0031-6997(24)01511-4","article-title":"International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors","volume":"53","author":"Fredholm","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0015","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1126\/science.1164772","article-title":"The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist","volume":"322","author":"Jaakola","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0020","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1021\/jm901647p","article-title":"Structure-based discovery of novel chemotypes for adenosine A2A receptor antagonists","volume":"53","author":"Katritch","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0025","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1021\/jm100240h","article-title":"Structure-based discovery of adenosine A2A receptor ligands","volume":"53","author":"Carlsson","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0030","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.brainresrev.2008.06.002","article-title":"Novel pharmacological targets based on receptor heteromers","volume":"58","author":"Franco","year":"2008","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0035","doi-asserted-by":"crossref","first-page":"46741","DOI":"10.1074\/jbc.M306451200","article-title":"Adenosine A2A-dopamine D2 receptor\u2013receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer","volume":"278","author":"Canals","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0040","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nmeth.1229","article-title":"Detection of heteromerization of more than two proteins by sequential BRET\u2013FRET","volume":"5","author":"Carriba","year":"2008","journal-title":"Nat. Meth."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0045","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nchembio0309-131","article-title":"Building a new conceptual framework for receptor heteromers","volume":"5","author":"Ferr\u00e9","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0050","doi-asserted-by":"crossref","first-page":"8606","DOI":"10.1073\/pnas.150241097","article-title":"Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes","volume":"97","author":"Gin\u00e9s","year":"2000","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11302-009-9140-8","article-title":"Recent improvements in the development of A2B adenosine receptor agonists","volume":"5","author":"Baraldi","year":"2009","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0060","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11302-008-9119-x","article-title":"Progress in the discovery of selective, high affinity A2B adenosine receptor antagonists as clinical candidates","volume":"5","author":"Kalla","year":"2009","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0065","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2174\/156802610791268747","article-title":"A2B receptor ligands: past, present and future trends","volume":"10","author":"Ortore","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0070","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1021\/jm900413e","article-title":"1-Alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity","volume":"52","author":"Borrmann","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0075","doi-asserted-by":"crossref","unstructured":"C.E. M\u00fcller, K.A. Jacobson, Xanthines as adenosine receptor antagonists. In Methylxanthines. In Handbook of Experimental Pharmacology, B.B. Fredholm, ed., Springer, 200 (2011) 151\u2013199.","DOI":"10.1007\/978-3-642-13443-2_6"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0080","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2174\/1389557510101040417","article-title":"A3 adenosine receptor antagonists","volume":"1","author":"M\u00fcller","year":"2001","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0085","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2174\/1568026033392174","article-title":"Medicinal chemistry of adenosine A3 receptor ligands","volume":"3","author":"M\u00fcller","year":"2003","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0090","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1517\/13543776.7.5.419","article-title":"A1-adenosine receptor antagonists","volume":"7","author":"M\u00fcller","year":"1997","journal-title":"Exp. Opin. Ther. Pat."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0095","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0006-2952(03)00153-9","article-title":"N6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors","volume":"65","author":"Gao","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0100","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0014-5793(86)81096-1","article-title":"Species differences in structure\u2013activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors","volume":"209","author":"Ukena","year":"1986","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0031-6865(93)90012-U","article-title":"Adenosine receptors and their modulators","volume":"68","author":"M\u00fcller","year":"1993","journal-title":"Pharm. Acta Helv."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0110","doi-asserted-by":"crossref","first-page":"534","DOI":"10.5414\/CPP42534","article-title":"Tolerability, pharmacokinetics, and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men","volume":"42","author":"van Troostenburg","year":"2004","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11302-007-9086-7","article-title":"Internalization and desensitization of adenosine receptors","volume":"4","author":"Klaasse","year":"2008","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0120","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2174\/1381612802666221004174507","article-title":"Adenosine receptor antagonists: structures and potential therapeutic applications","volume":"2","author":"M\u00fcller","year":"1996","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0125","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/cmdc.200600066","article-title":"Improving potency, selectivity, and water-solubility of adenosine A1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd]purinediones","volume":"1","author":"Weyler","year":"2006","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0130","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1021\/jm9911480","article-title":"Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A2A-selective adenosine receptor antagonists","volume":"43","author":"Sauer","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0135","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3390\/molecules13020348","article-title":"Synthesis and properties of a new water-soluble prodrug of the adenosine A2A receptor antagonist MSX-2","volume":"13","author":"Vollmann","year":"2008","journal-title":"Molecules"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0140","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1021\/jm011093d","article-title":"Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A2A- and A3-adenosine receptor antagonists","volume":"45","author":"M\u00fcller","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0145","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2174\/1381612023392955","article-title":"Applications of adenosine receptor ligands in medical imaging by positron emission tomography","volume":"8","author":"Holschbach","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0150","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1096\/fj.07-8180com","article-title":"Agonist-occupied A3 adenosine receptors exist within heterogeneous complexes in membrane microdomains of individual living cells","volume":"22","author":"Cordeaux","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0155","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1021\/jm061279i","article-title":"New fluorescent adenosine A1 receptor agonists that allow quantification of single living cells","volume":"50","author":"Middleton","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0160","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.bcp.2010.04.027","article-title":"Novel Alexa Fluor-488 labeled antagonist of the A2A adenosine receptor: application to a fluorescence polarization-based receptor binding assay","volume":"80","author":"Kecsk\u00e9s","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0165","unstructured":"U. Rosentreter, R. Henning, M. Bauser, T. Kramer, A. Vaupel, W. Hubsch, K. Dembowsky, O. Salcher-Schrauf-Stetter, J.P. Stasch, T. Krahn, E. Petzborn, Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof. WO Pat. 2001\/025210."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0170","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1021\/jm049947s","article-title":"New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine","volume":"47","author":"Beukers","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0175","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1517\/14728214.8.2.537","article-title":"Adenosine receptor agonists: from basic medicinal chemistry to clinical development","volume":"8","author":"Yan","year":"2003","journal-title":"Exp. Opin. Emerg. Drugs"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0180","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-3-540-89615-9_2","article-title":"A1 adenosine receptor antagonists, agonists, and allosteric enhancers","volume":"193","author":"Kiesman","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0185","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0014-2999(02)01552-2","article-title":"2-Chloro-N6-cyclopentyladenosine, adenosine A1 receptor agonist, antagonizes the adenosine A3 receptor","volume":"443","author":"Gao","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0190","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-3-540-89615-9_3","article-title":"Recent developments in adenosine A2A receptor ligands","volume":"193","author":"Cristalli","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0195","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2174\/156802610791268765","article-title":"A2A receptor ligands: past, present and future trends","volume":"10","author":"Clementina","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0200","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2008.05.036","article-title":"Adenosine A2A receptor dynamics studied with the novel fluorescent agonist Alexa488-APEC","volume":"590","author":"Brand","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0205","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1021\/bc9001689","article-title":"PEGylated dendritic unimolecular micelles as versatile carriers for ligands of G protein-coupled receptors","volume":"20","author":"Kim","year":"2009","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0210","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1021\/jm801533x","article-title":"Evaluation of homology modeling of G protein-coupled receptors in light of the A2A adenosine receptor crystallographic structure","volume":"52","author":"Ivanov","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0215","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s10822-009-9299-7","article-title":"Homology modelling of the human adenosine A2B receptor based on X-ray structures of bovine rhodopsin, the \u03b22-adrenergic receptor and the human adenosine A2A receptor","volume":"23","author":"Sherbiny","year":"2009","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0220","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1016\/j.bmcl.2009.05.027","article-title":"SAR of a series of inhaled A2A agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data","volume":"19","author":"Mantell","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0225","doi-asserted-by":"crossref","first-page":"7669","DOI":"10.1021\/jm900538v","article-title":"Nucleoside-5\u2032-monophosphates as prodrugs of adenosine A2A receptor agonists activated by ecto-5\u2032-nucleotidase","volume":"52","author":"El-Tayeb","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0230","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1021\/jm061170a","article-title":"Synthesis and biological evaluation of novel 1-deoxy-1-[6-[((hetero)arylcarbonyl)hydrazine]-9H-purin-9-yl]-N-ethyl-\u03b2-d-ribofuranuronamide derivatives as useful templates for the development of A2B adenosine receptor agonists","volume":"50","author":"Baraldi","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0235","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1021\/jm061278q","article-title":"Structure\u2013activity relationships of 2,N6,5\u2032-substituted adenosine derivatives with potent activity at the A2B adenosine receptor","volume":"50","author":"Adachi","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0240","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00395-007-0687-7","article-title":"Adenosine: trigger and mediator of cardioprotection","volume":"103","author":"Cohen","year":"2008","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0245","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1161\/CIRCULATIONAHA.106.669697","article-title":"Cardioprotection by ecto-5\u2032-nucleotidase (CD73) and A2B adenosine receptors","volume":"115","author":"Eckle","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0250","series-title":"HEP Adenosine Receptors in Health and Disease","first-page":"123","article-title":"Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering","volume":"193","author":"Jacobson","year":"2009"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0255","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1016\/j.bmc.2010.03.047","article-title":"Synthesis and evaluation of new N6-substituted adenosine-5\u2032-N-methylcarboxamides as A3 adenosine receptor agonists","volume":"18","author":"Devine","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0260","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1021\/jm900754g","article-title":"Synthesis and biological evaluation of 2-alkynyl-N6-methyl-5\u2032-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A3 receptor","volume":"52","author":"Volpini","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0265","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1021\/jm034098e","article-title":"N6-Substituted d-4\u2032-thioadenosine-5\u2032-methyluronamides: potent and selective agonists at the human A3 adenosine receptor","volume":"46","author":"Jeong","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0270","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1021\/jm049580r","article-title":"(N)-Methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists","volume":"48","author":"Tchilibon","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0275","doi-asserted-by":"crossref","first-page":"8546","DOI":"10.1016\/j.bmc.2008.08.007","article-title":"Selective A3 adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system","volume":"16","author":"Melman","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0280","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-3155-6-12","article-title":"Enhanced A3 adenosine receptor selectivity of multivalent nucleoside\u2013dendrimer conjugates","volume":"6","author":"Klutz","year":"2008","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0285","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1021\/cr0682195","article-title":"Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility","volume":"108","author":"Baraldi","year":"2008","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0290","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/med.20048","article-title":"Progress in the pursuit of therapeutic adenosine receptor antagonists","volume":"26","author":"Moro","year":"2006","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0295","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2174\/156802610791268729","article-title":"A1 receptors ligands: past, present, and future trends","volume":"10","author":"Schenone","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0300","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1517\/14656560802682213","article-title":"Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure","volume":"10","author":"Slawski","year":"2009","journal-title":"Exp. Opin. Pharmacother."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0305","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1021\/jm970013w","article-title":"Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbornyl)]xanthin","volume":"40","author":"Pfister","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0310","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1002\/cbdv.200900114","article-title":"Prodrug approaches for enhancing the bioavailability of drugs with low solubility","volume":"6","author":"M\u00fcller","year":"2009","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0315","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.bmc.2010.01.072","article-title":"2-Amino-5-benzoyl-4-phenylthiazoles: development of potent and selective adenosine A1 receptor antagonists","volume":"18","author":"Scheiff","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157488907779561772","article-title":"Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders","volume":"2","author":"M\u00fcller","year":"2007","journal-title":"Recent Pat. CNS Drug Discov."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0325","doi-asserted-by":"crossref","unstructured":"C.E. M\u00fcller, S. Ferr\u00e9, Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders, Frontiers in CNS Drug Discov 1 (2010) 304\u2013341.","DOI":"10.2174\/978160805159511001010304"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0330","first-page":"466","article-title":"Recent progress in the discovery of adenosine A2A receptor antagonists for the treatment of Parkinson's disease","volume":"13","author":"Shah","year":"2010","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0335","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1124\/jpet.103.056036","article-title":"Antinociceptive effects of novel A2B adenosine receptor antagonists","volume":"308","author":"Abo-Salem","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0340","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00210-007-0252-9","volume":"377","author":"Bilkei-Gorzo","year":"2008","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0345","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00213-008-1441-z","article-title":"The adenosine A2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost\/benefit procedure","volume":"204","author":"Mott","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0350","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00213-008-1396-0","article-title":"The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists","volume":"203","author":"Worden","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0355","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0014-2999(00)00899-2","article-title":"[3H]ZM241385 \u2014 an antagonist radioligand for adenosine A2A receptors in brain","volume":"411","author":"Alexander","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0360","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1016\/j.bmc.2010.02.039","article-title":"Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: a preliminary inspection of ligand\u2013receptor recognition process","volume":"18","author":"Pastorin","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0365","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1021\/jm0009843","article-title":"Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A2A receptor system using positron emission tomography","volume":"43","author":"Todde","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0370","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1016\/j.bmcl.2010.04.058","article-title":"Synthetic studies on selective adenosine A2A receptor antagonists. Part II: synthesis and structure\u2013activity relationships of novel benzofuran derivatives","volume":"20","author":"Saku","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0375","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.bmcl.2009.11.133","article-title":"Synthesis of novel 7-imino-2-thioxo-3,7-dihydro-2H-thiazolo[4,5-d]pyrimidine derivatives as adenosine A2A receptor antagonists","volume":"20","author":"Luthra","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0380","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.bmc.2010.02.048","article-title":"Novel 8-(furan-2-yl)-3-substituted thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidine-2(3H)-thione derivatives as potential adenosine A2A receptor antagonists","volume":"18","author":"Mishra","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0385","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.2174\/138161206777585265","article-title":"Ligand-based homology modeling as attractive tool to inspect GPCR structural plasticity","volume":"12","author":"Moro","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0390","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.bcp.2009.11.009","article-title":"Synthesis and pharmacological characterization of [125I]MRS5127, a high affinity, selective agonist radioligand for the A3 adenosine receptor","volume":"79","author":"Auchampach","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0395","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1021\/jm8008647","article-title":"Structure activity relationships of truncated d- and l-4\u2032-thioadenosine derivatives as species-independent A3 adenosine receptor antagonists","volume":"51","author":"Jeong","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0400","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.exer.2009.10.001","article-title":"Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species","volume":"90","author":"Wang","year":"2010","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0405","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1177\/00912700022009503","article-title":"Pharmacokinetics and safety of single intravenous infusions of the adenosine agonist, AMP 579, in patients with end-stage renal insufficiency","volume":"40","author":"Zannikos","year":"2000","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0410","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0002-8703(03)00172-8","volume":"146","author":"Kopecky","year":"2003","journal-title":"Am. Heart J."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0415","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00395-009-0056-9","article-title":"AMP579 is revealed to be a potent A2b-adenosine receptor agonist in human 293 cells and rabbit hearts","volume":"105","author":"Liu","year":"2010","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0420","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/smrv.2001.0201","article-title":"Adenosine and sleep","volume":"6","author":"Porkka-Heiskanen","year":"2002","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0425","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1523\/JNEUROSCI.5066-06.2007","article-title":"Sleep deprivation increases A1 adenosine receptor binding in the human brain: a positron emission tomography study","volume":"27","author":"Elmenhorst","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0430","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1038\/sj.bjp.0707524","article-title":"Suppression of inflammatory and immune responses by the A2A adenosine receptor: an introduction","volume":"153","author":"Palmer","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0435","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1073\/pnas.0705563105","article-title":"The A2b adenosine receptor protects against vascular injury","volume":"105","author":"Yang","year":"2008","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0440","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/00054725-200608000-00014","volume":"12","author":"Guzman","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0445","doi-asserted-by":"crossref","first-page":"G401","DOI":"10.1152\/ajpgi.00454.2007","article-title":"Purinergic receptors in gastrointestinal inflammation","volume":"294","author":"Kolachala","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0450","first-page":"20","article-title":"Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level","volume":"34","author":"Madi","year":"2007","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0455","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0168-8227(97)00116-2","article-title":"Hypoglycemic and hypotensive effects of 6-cyclohexyl-2\u2032-O-methyl-adenosine, an adenosine A1 receptor agonist, in spontaneously hypertensive rat complicated with hyperglycemia","volume":"39","author":"Ishikawa","year":"1998","journal-title":"Diab. Res. Clin. Pract."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0460","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/npp.2010.26","article-title":"Adenosine A1 receptors and microglial cells mediate CX3CL1-induced protection of hippocampal neurons against Glu-induced death","volume":"35","author":"Lauro","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0465","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1021\/jm960682u","article-title":"N-Substituted adenosines as novel neuroprotective A1 agonists with diminished hypotensive effects","volume":"42","author":"Knutsen","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0470","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1046\/j.1468-2982.2003.00511.x","article-title":"Effect of the adenosine A1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects","volume":"23","author":"Giffin","year":"2003","journal-title":"Cephalalgia"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0475","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00045391-200405000-00005","article-title":"Pharmacokinetics, pharmacodynamics, and safety of a lipid-lowering adenosine A1 agonist, RPR749, in healthy subjects","volume":"11","author":"Shah","year":"2004","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0480","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2174\/1568026043450998","article-title":"Partial A1 adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation (AF)","volume":"4","author":"Zablocki","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0485","doi-asserted-by":"crossref","first-page":"F828","DOI":"10.1152\/ajprenal.00310.2005","article-title":"Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy","volume":"290","author":"Awad","year":"2006","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0490","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1124\/mol.104.007807","article-title":"Adenosine A2A receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin 1","volume":"67","author":"Desai","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0495","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1161\/01.CIR.0000114523.03312.7D","article-title":"Randomized, controlled dose-ranging study of the selective adenosine A2A receptor agonist binodenoson for pharmacological stress as an adjunct to myocardial perfusion imaging","volume":"109","author":"Udelson","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0500","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11886-006-0022-1","article-title":"Advances in pharmacologic agents in imaging: new A2A receptor agonists","volume":"8","author":"Cerqueira","year":"2006","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0505","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.nuclcard.2007.06.114","article-title":"Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial","volume":"14","author":"Iskandrian","year":"2007","journal-title":"J. Nucl. Cardiol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0510","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ophtha.2009.11.029","article-title":"Treatment of dry eye syndrome with orally-administered CF101: data from a phase 2 clinical trial","volume":"117","author":"Avni","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0515","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1124\/jpet.107.127480","article-title":"The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3\u2032-aminoadenosine-5\u2032-N-methylcarboxamide] protects against myocardial ischemia\/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel","volume":"324","author":"Wan","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0520","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1440-1754.2009.01570.x","article-title":"Caffeine versus theophylline for apnea of prematurity: a randomized controlled trial","volume":"45","author":"Skouroliakou","year":"2009","journal-title":"J. Paediatr. Child Health"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0525","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2174\/138945006777435236","article-title":"Adenosine receptors as promising therapeutic targets for drug development in chronic airway inflammation","volume":"7","author":"Polosa","year":"2006","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0530","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11897-008-0017-x","article-title":"Adenosine A1 antagonists and the cardiorenal syndrome","volume":"5","author":"Gottlieb","year":"2008","journal-title":"Curr. Heart Fail. Rep."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0535","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1124\/mol.107.038760","volume":"72","author":"Che","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0540","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/02713680590953147","article-title":"The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure","volume":"30","author":"Yang","year":"2005","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0545","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrd1983","article-title":"Adenosine receptors as therapeutic targets","volume":"5","author":"Jacobson","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0550","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1074\/jbc.273.10.5727","article-title":"Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX)","volume":"273","author":"Arispe","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0555","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/bjp.2008.361","article-title":"Adenosine receptors and asthma in humans","volume":"155","author":"Wilson","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0560","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1517\/13543776.11.10.1533","article-title":"Recent advances in adenosine receptor antagonist research","volume":"11","author":"Hess","year":"2001","journal-title":"Exp. Opin. Ther. Pat."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0565","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0014-2999(95)00165-H","article-title":"A novel non-xanthine adenosine A1 receptor antagonist","volume":"279","author":"Terai","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0570","doi-asserted-by":"crossref","unstructured":"B. Hocher, Adenosine A1 receptor antagonists in clinical research and development, Kidney Int. 78 (2010) 438\u2013445.","DOI":"10.1038\/ki.2010.204"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0575","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.21315","article-title":"Adenosine A2A receptor antagonist istradefylline (KW6002) reduces \u201coff\u201d time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)","volume":"63","author":"LeWitt","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0580","first-page":"A682","article-title":"QAF805, an A2B\/A3 antagonist, does not attenuate AMP challenge in subjects with asthma","author":"Pascoe","year":"2007","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0585","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1016\/j.bmcl.2004.04.099","article-title":"Structure\u2013activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma","volume":"14","author":"Okamura","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0590","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/978-3-540-89615-9_10","article-title":"A3 adenosine receptor: pharmacology and role in disease","volume":"193","author":"Borea","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0595","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/978-3-540-89615-9_19","article-title":"Adenosine receptor ligands and PET imaging in the CNS","author":"Bauer","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0600","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0969-8043(95)00295-2","article-title":"Synthesis and preliminary evaluation of [11C]KF17837, a selective adenosine A2A antagonist","volume":"47","author":"Ishiwata","year":"1996","journal-title":"Appl. Radiat. Isot."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0605","first-page":"498","article-title":"Evaluation of carbon-11-labeled KF17837: a potential CNS adenosine A2a receptor ligand","volume":"39","author":"Noguchi","year":"1998","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0610","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0969-8043(98)00162-6","article-title":"Preparation and primary evaluation of [11C]CSC as a possible tracer for mapping adenosine A2A receptors by PET","volume":"50","author":"M\u00e1ri\u00e1n","year":"1999","journal-title":"App. Radiat. Isot."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0615","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF02988206","article-title":"Evaluation of iodinated and brominated [11C]styrylxanthine derivatives as in vivo radioligands mapping adenosine A2A receptor in the central nervous system","volume":"14","author":"Ishiwata","year":"2000","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0620","first-page":"345","article-title":"11C-labeled KF18446: a potential central nervous system adenosine A2A receptor ligand","volume":"41","author":"Ishiwata","year":"2000","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0625","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00259-004-1688-5","article-title":"In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416","volume":"32","author":"Moresco","year":"2005","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0630","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.nucmedbio.2007.09.004","article-title":"Preparation and first evaluation of [18F]FEQSUPPY: a new PET tracer for the adenosine A3 receptor","volume":"35","author":"Wadsak","year":"2008","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0635","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.nucmedbio.2008.10.003","article-title":"Synthesis and characterization of [76Br]-labeled high affinity A3 adenosine receptor ligands for positron emission tomography","volume":"36","author":"Kiesewetter","year":"2009","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0640","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1517\/14728214.8.2.537","article-title":"Adenosine receptor agonists: from basic medicinal chemistry to clinical development","volume":"8","author":"Yan","year":"2003","journal-title":"Exp. Opin. Emerg. Drugs"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0645","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000139033","article-title":"Structure\u2013activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors","volume":"46","author":"Daly","year":"1993","journal-title":"Pharmacology"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0650","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1139\/y80-110","article-title":"Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists","volume":"58","author":"Bruns","year":"1980","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0655","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0006-2952(94)90480-4","article-title":"Functional characterization of the A2b adenosine receptor in NIH 3T3 fibroblasts","volume":"47","author":"Brackett","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0660","doi-asserted-by":"crossref","first-page":"10365","DOI":"10.1073\/pnas.90.21.10365","article-title":"Molecular cloning and characterization of the human A3 adenosine receptor","volume":"90","author":"Salvatore","year":"1993","journal-title":"Proc. Natl Acad. Sci."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0665","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0026-895X(25)10559-2","article-title":"A binding site model and structure\u2013activity relationships for the rat A3 adenosine binding site","volume":"45","author":"van Galen","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0670","series-title":"A3 Adenosine Receptors From Cell Biology to Pharmacology","first-page":"257","author":"Liang","year":"2010"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0675","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1517\/13543780802497284","article-title":"A1 adenosine receptor agonists and their potential therapeutic applications","volume":"17","author":"Elzein","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0680","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0022-3565(24)37630-X","article-title":"Cardioprotective effects of the novel adenosine A1\/A2 receptor agonist AMP 579 in a porcine model of myocardial infarction","volume":"286","author":"Smits","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0685","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1080\/00397919608003819","article-title":"A practical synthesis of SDZ WAG 994 by selective methylation of N6-cyclohexyladenosine","volume":"26","author":"Prashad","year":"1996","journal-title":"Synth. Commun."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0690","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.bmcl.2009.11.131","article-title":"Synthesis and evaluation of two series of 4\u2032-aza-carbocyclic nucleosides as adenosine A2A receptor agonists","volume":"20","author":"Beattie","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.bbamem.2010.12.017_bb0695","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.bcp.2008.11.002","article-title":"Adenosine receptor agonists for promotion of dermal wound healing","volume":"77","author":"Valls","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0700","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.yjmcc.2007.05.016","article-title":"Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion","volume":"43","author":"Kuno","year":"2007","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0705","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.108.148270","article-title":"Characterization of the A2B adenosine receptor from mouse, rabbit, and dog","volume":"329","author":"Auchampach","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0710","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1021\/jm050595e","article-title":"Structure\u2013activity relationships of 2-chloro-N6-substituted-4\u2032-thioadenosine-5\u2032-uronamides as highly potent and selective agonists at the human A3 adenosine receptor","volume":"49","author":"Jeong","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0715","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1016\/j.bmcl.2008.04.001","article-title":"Design of (N)-methanocarba adenosine 5\u2032-uronamides as species-independent A3 receptor-selective agonists","volume":"18","author":"Melman","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0720","doi-asserted-by":"crossref","first-page":"H2780","DOI":"10.1152\/ajpheart.00411.2003","article-title":"Novel N6-substituted adenosine 5\u2032-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury","volume":"285","author":"Tracey","year":"2003","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0725","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/(SICI)1098-2299(199905)47:1<45::AID-DDR6>3.0.CO;2-U","article-title":"1,3-Dialkylxanthine derivatives having high potency as antagonists at human A2B adenosine receptors","volume":"47","author":"Jacobson","year":"1999","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0730","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1021\/jm00036a019","article-title":"Synthesis and structure\u2013activity relationships of deazaxanthines: analogs of potent A1- and A2-adenosine receptor antagonists","volume":"37","author":"Grahner","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0735","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000138813","article-title":"Caffeine analogs: structure\u2013activity relationships at adenosine receptors","volume":"42","author":"Daly","year":"1991","journal-title":"Pharmacology"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0740","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0928-0987(00)00064-6","article-title":"Binding of [3H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes \u2014 a new, selective antagonist radioligand for A2A adenosine receptors","volume":"10","author":"M\u00fcller","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0745","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1021\/jm0104318","article-title":"Structure\u2013activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions","volume":"45","author":"Kim","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0750","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s11302-006-9012-4","article-title":"Characterization of human and rodent native and recombinant adenosine A2B receptors by radioligand binding studies","volume":"2","author":"Bertarelli","year":"2006","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0755","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1021\/jm00074a015","article-title":"Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure\u2013activity relationships at adenosine receptors","volume":"36","author":"M\u00fcller","year":"1993","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0760","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/BF00168610","article-title":"Comparison of adenosine receptors in brain from different species by radioligand binding and photoaffinity labelling","volume":"343","author":"Klotz","year":"1991","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0765","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0014-2999(03)02078-8","article-title":"Antagonist pharmacology of adenosine A2B receptors from rat, guinea pig and dog","volume":"475","author":"Fozard","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0770","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1021\/bc00033a004","article-title":"A \u201ccleavable trifunctional\u201d approach to receptor affinity labeling: regeneration of binding to A1-adenosine receptors","volume":"6","author":"Jacobson","year":"1995","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0775","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1124\/mol.52.5.846","article-title":"Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor","volume":"52","author":"Auchampach","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0780","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1021\/jm011049y","article-title":"1,8-Disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists","volume":"45","author":"Hayallah","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0785","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1016\/j.bmc.2006.01.021","article-title":"Norbornyllactone-substituted xanthines as adenosine A1 receptor antagonists","volume":"14","author":"Kiesman","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0790","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.1021\/jm0605381","article-title":"Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists","volume":"49","author":"Kiesman","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0795","first-page":"962","article-title":"BG-9928 (Biogen Idec)","volume":"6","author":"Doggrell","year":"2005","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0800","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/sj.bjp.0707319","article-title":"The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5\/6 nephrectomy without affecting blood pressure","volume":"151","author":"Kalk","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0805","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1124\/jpet.105.088179","article-title":"A novel A1 adenosine receptor antagonist, L-97-1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino]-ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma","volume":"315","author":"Obiefuna","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0810","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1212\/01.WNL.0000095219.22086.31","article-title":"The adenosine A2A receptor selective antagonist KW6002: research toward a novel nondopaminergic therapy for Parkinson's disease","volume":"61","author":"Kase","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0815","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/S0960-894X(97)00440-X","article-title":"Adenosine A2A antagonists with potent anti-cataleptic activity","volume":"7","author":"Shimada","year":"1997","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0820","doi-asserted-by":"crossref","first-page":"8676","DOI":"10.1016\/j.bmc.2008.07.088","article-title":"Dual inhibition of monoamine oxidase B and antagonism of the adenosine A2A receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues","volume":"16","author":"Pretorius","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0825","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1021\/jm00062a005","article-title":"Structure\u2013activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists","volume":"36","author":"Jacobson","year":"1993","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0830","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1021\/jm800961g","article-title":"Antagonists of the human A2A receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines","volume":"52","author":"Gillespie","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0835","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1021\/jm058018d","article-title":"2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization","volume":"48","author":"Minetti","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0840","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1021\/jm990421v","article-title":"Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A2B adenosine receptors","volume":"43","author":"Kim","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0845","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1021\/jm0309654","article-title":"Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists","volume":"47","author":"Baraldi","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0850","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1021\/jm7014815","article-title":"Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases","volume":"51","author":"Elzein","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0855","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.bmcl.2010.01.045","article-title":"Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A2B adenosine receptor antagonists","volume":"20","author":"Eastwood","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0860","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1021\/jm061333v","article-title":"Discovery and characterization of 4\u2032-(2-furyl)-N-pyridin-3-yl-4,5\u2032-bipyridmidin-2\u2032-amine (LAS38096), a potent, selective, and efficacious A2B adenosine receptor antagonist","volume":"50","author":"Vidal","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0865","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.1016\/j.bmcl.2009.08.040","article-title":"Discovery and optimization of potent and selective functional antagonists of the human adenosine A2B receptor","volume":"19","author":"Bedford","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0870","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1016\/j.bmcl.2010.05.056","article-title":"4-Substituted-7-N-alkyl-N-acetyl 2-aminobenzothiazole amides: drug-like and non-xanthine based A2B adenosine receptor antagonists","volume":"20","author":"Cheung","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0875","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.bmcl.2010.01.077","article-title":"Discovery of potent and selective bicyclic A2B adenosine receptor antagonists via bioisosteric amide replacement","volume":"20","author":"Eastwood","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0880","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bcp.2004.03.026","article-title":"[3H]OSIP339391, a selective, novel, and high affinity antagonist radioligand for adenosine A2B receptors","volume":"68","author":"Stewart","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0885","series-title":"A3 Adenosine Receptors From Cell Biology to Pharmacology","author":"Fozard","year":"2010"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0890","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1021\/jm100049f","volume":"53","author":"Cheong","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0895","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/jm000002u","article-title":"Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A3 receptor","volume":"43","author":"van Muijlwijk-Koezen","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0900","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0014-2999(02)01662-X","article-title":"KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A3 receptor antagonist","volume":"444","author":"Saki","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0905","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0968-0896(02)00456-X","article-title":"2-Phenylimidazo[2,1-i]purin-5-ones: structure\u2013activity relationships and characterization of potent and selective inverse agonists at human A3 adenosine receptors","volume":"11","author":"Ozola","year":"2003","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0910","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0960-894X(01)00785-5","article-title":"[3H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]purin-5-one ([3H]PSB-11), a novel high-affinity antagonist radioligand for human A3 adenosine receptors","volume":"12","author":"M\u00fcller","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0915","doi-asserted-by":"crossref","first-page":"7640","DOI":"10.1021\/jm900718w","article-title":"2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition","volume":"52","author":"Lenzi","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0920","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1016\/j.bmc.2009.03.034","article-title":"Structure\u2013activity relationships of truncated adenosine derivatives as highly potent and selective human A3 adenosine receptor antagonists","volume":"17","author":"Pal","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0925","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1254\/jphs.FP0040359","article-title":"Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors","volume":"96","author":"Maemoto","year":"2004","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0930","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0026-895X(25)09820-7","article-title":"Binding of [3H]KF17837S, a selective adenosine A2 receptor antagonist, to rat brain membranes","volume":"46","author":"Nonaka","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0935","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1021\/jm970515+","article-title":"Synthesis and structure\u2013activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists","volume":"40","author":"M\u00fcller","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0940","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1358\/dof.2000.025.10.858696","article-title":"A2A Adenosine receptor antagonists \u2014 future drugs for Parkinson's disease?","volume":"25","author":"M\u00fcller","year":"2000","journal-title":"Drugs Fut."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0945","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1021\/jm980550w","article-title":"Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists","volume":"42","author":"Li","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamem.2010.12.017_bb0950","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/syn.1110","article-title":"Evaluation of [4-O-methyl-11C]KW-6002 as a potential PET ligand for mapping central adenosine A2A receptors in rats","volume":"42","author":"Hirani","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.bbamem.2010.12.017_bb0955","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2009.04.089","article-title":"Regadenoson: a new myocardial stress agent","volume":"54","author":"Al Jaroudi","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bbamem.2010.12.017_bb1000","doi-asserted-by":"crossref","unstructured":"P. Eastwood, C. Esteve, J. Gonz\u00e1lez, S. Fonquerna, J. Aiguad\u00e9, I. Carranco, T. Dom\u00e9nech, M. Aparici, M. Miralpeix, J. Albert\u00ed, M. C\u00f3rdoba, R, Fern\u00e1ndez, M. Pont, N. Godessart, N. Prats, M. I. Loza, M. I. Cadavid, A. Nueda, B. Vidal, Discovery of LAS101057: a potent, selective, and orally efficacious A2B adenosine receptor antagonist. ACS Med. Chem. Lett. 1 (in press) doi:10.1021\/ml100249e.","DOI":"10.1021\/ml100249e"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Biomembranes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0005273610004529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0005273610004529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T13:47:09Z","timestamp":1762091229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0005273610004529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":192,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0005273610004529"],"URL":"https:\/\/doi.org\/10.1016\/j.bbamem.2010.12.017","relation":{},"ISSN":["0005-2736"],"issn-type":[{"value":"0005-2736","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent developments in adenosine receptor ligands and their potential as novel drugs","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Biomembranes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbamem.2010.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier B.V. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}